The board of directors of Simcere Pharmaceutical Group Limited announced that, on November 25, 2021, the marketing of ENWEIDA (generic name: Envafolimab) in China, which is a single domain antibody against recombinant humanized PD-L1 and a protein fused with Fc, developed by the Group in collaboration with 3D Medicines (Beijing) Co. Ltd. (?3D (Beijing) Medicines?) and Jiangsu Alphamab Biopharmaceuticals Co. Ltd. (?Jiangsu Alphamab?), has formally obtained the conditional approval by the National Medical Products Administration (the ?NMPA?), applicable for treatment of adult patients with advanced solid tumors who have unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair gene-deficient (dMMR), including those patients with advanced colorectal cancer who have experienced disease progression after being treated with fluorouracil, oxaliplatin and irinotecan previously, as well as other patients with advanced solid tumors who have experienced disease progression after previous treatment and no satisfactory treatment alternatives. ENWEIDA is the world's first PD-1/PD-L1 antibody to be administered by subcutaneous injection approved for marketing. Its unique method of injection differentiates itself from other PD-1/PD-L1 products currently on the market, with the advantages of short administration time and good safety profile. The launch of ENWEIDA will provide Chinese patients with a high quality and more convenient PD-L1 antibody. On March 30, 2020, the Group entered into a tripartite cooperation agreement in relation to Envafolimab with 3D (Beijing) Medicines and Jiangsu Alphamab. The abovementioned agreement provides them with the exclusive right to promote Envafolimab for oncology indications and the right of first refusal under external license or transfer in Mainland China.